|Dr. Ali Fattaey||CEO, Pres & Director||716.43k||N/A||1965|
|Mr. James E. Dentzer||COO, CFO & Chief Admin. Officer||470.35k||N/A||1967|
|Dr. David Tuck||Sr. VP & Chief Medical Officer||466.28k||N/A||1952|
|Mr. Daniel R. Passeri M.Sc., MSc., J.D.||Consultant||N/A||N/A||1961|
|Mr. Mark W. Noel||VP of Technology Management & Intellectual Property||N/A||N/A||1959|
Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Curis, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 7; Compensation: 7.